MYC and cancer: The TNA-E box-pomalidomide(TEP) conjugate specifically degrades endogenous c-Myc/Max in triple-negativebreast cancer cells.14 However, this importantapproach has some limitations, commonly faced with nanomedicines,such as the dosing complexities (cell transfection of TEP seems tobe essential for c-Myc degradation studies and efficacy studies inmouse models using liposome nanoparticles modified with cyclic RGDyKpeptides).14